HIV-1 Conserved Mosaics Delivered by Regimens with Integration-Deficient DC-Targeting Lentiviral Vector Induce Robust T Cells
Open accessThe DOI matches its Crossref record; 5 of the 5 references it cites were found in a registry or an index.
Abstract
To be effective against HIV type 1 (HIV-1), vaccine-induced T cells must selectively target epitopes, which are functionally conserved (present in the majority of currently circulating and reactivated HIV-1 strains) and, at the same time, beneficial (responses to which are associated with better clinical status and control of HIV-1 replication), and rapidly reach protective frequencies upon exposure to the virus.Heterologous primeboost regimens using virally vectored vaccines are currently the most promising vaccine strategies; nevertheless, induction of robust long-term memory remains challenging.To this end, lentiviral vectors induce high frequencies of memory cells due to their low-inflammatory nature, while typically inducing only low anti-vector immune responses.Here, we describe construction of novel candidate vaccines ZVex.tHIVconsv1 and ZVex.tHIVconsv2, which are based on an integration-deficient lentiviral vector platform with preferential transduction of human dendritic cells and express a bivalent mosaic of conservedregion T cell immunogens with a high global HIV-1 match.Each of the two mosaic vaccines was individually immunogenic.When administered together in heterologous primeboost regimens with chimpanzee adenovirus and/or poxvirus modified vaccinia virus Ankara (MVA) vaccines to BALB/c and outbred CD1-Swiss mice, they induced a median frequency of over 6,000 T cells/10 6 splenocytes, which were plurifunctional, broadly specific, and cross-reactive.These results support further development of this vaccine concept.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Buchbinder, S. P., Mehrotra, D. V., Duerr, A., Fitzgerald, D. W., Mogg, R., Li, D., Gilbert, P. B., Lama, J. R., Marmor, M., del Rio, C., et al. (2008) · The Lancet · doi:10.1016/s0140-6736(08)61591-3 · Cited by 1,713
CD8+ T cell efficacy in vaccination and disease
Appay, V., Douek, D. C., & Price, D. A. (2008) · Nature Medicine · doi:10.1038/nm.f.1774 · Cited by 393
Integrase-defective lentiviral vectors: Progress and applications
Banasik, M. B., & McCray, P. B. (2010) · Gene Therapy · doi:10.1038/gt.2009.135 · Cited by 129
Albershardt, T. C., Campbell, D. J., Parsons, A. J., Slough, M. M., ter Meulen, J., & Berglund, P. (2016) · Molecular Therapy - Oncolytics · doi:10.1038/mto.2016.10 · Cited by 38 · cited 2×
“IDLV was produced as described previously using the ZVex (also known as VP02) platform.(45,46,65) Briefly, ZVex ID-LV was produced via transient transfection of 293T cells with five plasmids: (1) the transfer vector that encodes the ZVex genome and tHIVconsv1 or tHIVconsv2, (2) a modified rev-independent gagpol transc…”
BackgroundMethodSelf-citationOdegard, J. M., Kelley-Clarke, B., Tareen, S. U., Campbell, D. J., Flynn, P. A., Nicolai, C. J., Slough, M. M., Vin, C. D., McGowan, P. J., Nelson, L. T., et al. (2015) · Journal of Immunotherapy · doi:10.1097/cji.0000000000000067 · Cited by 26 · cited 4×
“IDLV was produced as described previously using the ZVex (also known as VP02) platform.(45,46,65) Briefly, ZVex ID-LV was produced via transient transfection of 293T cells with five plasmids: (1) the transfer vector that encodes the ZVex genome and tHIVconsv1 or tHIVconsv2, (2) a modified rev-independent gagpol transc…”
BackgroundMethod
Cited by
Immune Responses to Viral Gene Therapy Vectors
Shirley, J. L., de Jong, Y. P., Terhorst, C., & Herzog, R. W. (2020) · Molecular Therapy · doi:10.1016/j.ymthe.2020.01.001 · Cited by 788
“, using integration-deficient LV vectors, is being exploited in vaccine development.(125,126) In hepatic gene transfer, use of a hepatocyte-specific promoter has not been sufficient to entirely prevent expression in APCs and activation of immune responses.”
MethodMoyo, N., Vogel, A. B., Buus, S., Erbar, S., Wee, E. G., Sahin, U., & Hanke, T. (2019) · Molecular Therapy - Methods & Clinical Development · doi:10.1016/j.omtm.2018.10.010 · Cited by 94
“The preparation of other vaccines used in this study was described before.(26,27)”
MethodSelf-citationThe old and the new: Prospects for non-integrating lentiviral vector technology
Apolonia, L. (2020) · Viruses · doi:10.3390/v12101103 · Cited by 58
Leleux, J. A., Albershardt, T. C., Parsons, A. J., ter Meulen, J., & Berglund, P. (2020) · Vaccine · doi:10.1016/j.vaccine.2020.08.003 · Cited by 5
Self-citation
Metadata
- Authors
- Wee, E. G., Ondondo, B., Berglund, P., Archer, J., McMichael, A. J., Baltimore, D., ter Meulen, J. H., & Hanke, T.
- Venue
- Molecular Therapy
- Publisher
- Elsevier BV
- Published
- 2017-02
- Volume
- 25
- Issue
- 2
- Pages
- 494-503
- ISSN
- 1525-0016 (ISSN-L)
- OpenAlex
- W2559372335
- Cited by
- 20
- References
- 5
- FWCI
- 1.80
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: HIV-1 Conserved Mosaics Delivered by Regimens with Integration-Deficient DC-Targeting Lentiviral Vector Induce Robust T Cells. https://app.cochat.ai/papers/10.1016/j.ymthe.2016.12.004
- The paper
- Wee, E. G., Ondondo, B., Berglund, P., Archer, J., McMichael, A. J., Baltimore, D., ter Meulen, J. H., & Hanke, T. (2017). HIV-1 Conserved Mosaics Delivered by Regimens with Integration-Deficient DC-Targeting Lentiviral Vector Induce Robust T Cells. Molecular Therapy. https://doi.org/10.1016/j.ymthe.2016.12.004
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.